Upstream Bio, Inc.
UPB
Last
$4.70
Day
+3.3%
1y
-77.0%
5y
-79.3%
52w
-86.5%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-0424d
EMA 21
5.19
EMA 50
5.86
EMA 200
9.82
20d high
-22.5%
5y high
-86.5%
5y range
1th
Positions held
Your positionsUPB isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-24
Hold
avoid
Signal
Strong Sell
Target
$5.11
Stop
$4.08
Stop distance
13.2%
Target vs last
+8.7%
Fundamentals
| Market cap | $249.21M | Enterprise value | -$11.14M | Trailing P/E | — | Forward P/E | -1.62 |
| PEG | — | Price / book | 0.92 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | -17.5% | Earnings growth | — | Gross margin | 100.0% | Operating margin | -54.8% |
| Profit margin | 0.0% | ROE | -46.1% | ROA | -30.3% | Debt / equity | 0.00 |
| Current ratio | 27.99 | Free cash flow | -$86.62M | Analyst recommendation | none | Mean target | $31.14 |
| 52w high | $33.68 | 52w low | $4.37 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.8M | $1.0M | $0.7M | $0.7M | $0.9M |
| Op margin | -5481.0% | -4218.1% | -6911.2% | -5539.4% | -4732.9% |
| Net income | -$39.7M | -$40.6M | -$42.5M | -$33.7M | -$40.0M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$42.4M | -$43.6M | -$46.2M | -$37.8M | -$44.3M |
- Revenue -25% vs prior quarter ($0.8M vs $1.0M).
- Operating margin compressed to -5481%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $2.9M | $2.4M | $2.4M | $1.2M |
| Op margin | -5618.8% | -3281.2% | -1685.5% | -1972.7% |
| Net income | -$143M | -$62.8M | -$20.5M | -$23.9M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$160M | -$77.8M | -$40.1M | -$23.9M |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-08 · Top Premarket Gainers
2026-09-01 · Upstream Bio on Track to Begin Two Phase 3 Verekitug Trials in Q1 2027
2026-08-11 · Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates
2026-08-11 · Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress
2026-07-14 · Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?
Price (daily)
Full chart · RSI · MACD · patternsUPB · daily-17.1% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin